Moreau P, et al. - In this two-part, randomized, open-label, phase 3 CASSIOPEIA trial, researchers determined if an improved stringent complete response rate could be achieved with the addition of daratumumab to bortezomib, thalidomide, and dexamethasone (VTd) before and after autologous stem-cell transplantation for newly diagnosed multiple myeloma. Either four pre-transplant induction and two post-transplant consolidation cycles of VTd alone (VTd group) or in combination with daratumumab (D-VTd group) were administered in a random manner (1:1) to transplant-eligible patients with newly diagnosed multiple myeloma. Part 2 (maintenance) is ongoing. Improvements in the depth of response and progression-free survival were reported in relation to treatment with D-VTd before and after autologous stem-cell transplantation. This treatment strategy had acceptable safety. In transplant-eligible patients with newly diagnosed multiple myeloma, daratumumab plus standard of care was shown to be clinically beneficial in the CASSIOPEIA study for the first time ever.